- Home
- AKBA vs LOT Comparison
AKBA vs LOT Comparison
Compare AKBA & LOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- LOT
- Stock Information
- Founded
- AKBA 2007
- LOT 1948
- Country
- AKBA United States
- LOT China
- Employees
- AKBA N/A
- LOT N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- LOT
- Sector
- AKBA Health Care
- LOT
- Exchange
- AKBA Nasdaq
- LOT NYSE
- Market Cap
- AKBA 958.6M
- LOT 956.3M
- IPO Year
- AKBA 2014
- LOT N/A
- Fundamental
- Price
- AKBA $3.69
- LOT $2.55
- Analyst Decision
- AKBA Strong Buy
- LOT
- Analyst Count
- AKBA 5
- LOT 0
- Target Price
- AKBA $6.90
- LOT N/A
- AVG Volume (30 Days)
- AKBA 6.6M
- LOT 72.2K
- Earning Date
- AKBA 08-07-2025
- LOT 06-25-2025
- Dividend Yield
- AKBA N/A
- LOT N/A
- EPS Growth
- AKBA N/A
- LOT N/A
- EPS
- AKBA N/A
- LOT N/A
- Revenue
- AKBA $184,909,000.00
- LOT $844,090,000.00
- Revenue This Year
- AKBA $26.88
- LOT $40.53
- Revenue Next Year
- AKBA $44.34
- LOT $87.99
- P/E Ratio
- AKBA N/A
- LOT N/A
- Revenue Growth
- AKBA N/A
- LOT 1.33
- 52 Week Low
- AKBA $0.80
- LOT $1.06
- 52 Week High
- AKBA $4.08
- LOT $7.42
- Technical
- Relative Strength Index (RSI)
- AKBA 63.96
- LOT 73.12
- Support Level
- AKBA $3.56
- LOT $2.02
- Resistance Level
- AKBA $3.87
- LOT $2.75
- Average True Range (ATR)
- AKBA 0.22
- LOT 0.12
- MACD
- AKBA -0.04
- LOT 0.03
- Stochastic Oscillator
- AKBA 36.53
- LOT 70.31
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.